QTNT QUOTIENT LTD

Quotient Limited Expands MosaiQ Innovator’s Circle to Empower Patient Care and Laboratory Efficiencies

Quotient Limited Expands MosaiQ Innovator’s Circle to Empower Patient Care and Laboratory Efficiencies

• The National Screening Laboratory of Sanquin Blood Supply Foundation joins MosaiQ Innovator’s Circle

JERSEY, Channel Islands, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced the National Screening Laboratory of Sanquin Blood Supply Foundation, Department Research & Labservices (Sanquin), headquartered in Amsterdam, the Netherlands has joined MosaiQ Innovator’s Circle. Sanquin Blood Supply is responsible for safe and efficient blood supply in the Netherlands.

The MosaiQ Innovator’s Circle is a community of experts, representing laboratories from nations around the world focused on transfusion medicine and other areas of clinical diagnostics. Members of the Innovator’s Circle partner with Quotient to create innovation and evidence generation to improve patient care and laboratory efficiencies.

“We believe in the power of fostering connections, and we’re honored to have Sanquin join our community of experts to achieve a common goal—improve clinical practices and transform patient care on a global scale,” said Manuel O. Méndez, Chief Executive Officer of Quotient.

“We are excited to be members of Quotient MosaiQ Innovator’s Circle to help drive innovation in transfusion medicine. At Sanquin, our mission is to ensure a better life for patients, and we believe this shared vision will help shape the future of diagnostics,” said Professor Gerald de Haan, at Sanquin Blood Supply Foundation.

About Sanquin Blood Supply Foundation

The Foundation is responsible for blood supply on a not-for-profit basis and advanced transfusion medicine as such that it fulfils the highest demands for quality, safety and efficiency. In addition to processing and supply blood products, Sanquin is engaged in diagnostic services, conducting research and providing education. Sanquin’s mission: "together with the donor for a better life of the patient."

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. The MosaiQ solution, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. The MosaiQ solution is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, and deliver significant workflow improvements and operational cost savings to laboratories around the world. Quotient’s operations are based in Switzerland, Scotland, US, and the UAE.

The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: Investor Relations, ; 6



EN
24/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUOTIENT LTD

 PRESS RELEASE

Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq ...

Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global Market JERSEY, Channel Islands, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the "Company") today announced that it has given formal notice to the Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market. In order to implement the delisting, the Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on or about December 27, 2022. The delisting of the Company's ordinary shares will take effec...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: November 2, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Quotient Limited Announces Reverse Stock Split Effective Today

Quotient Limited Announces Reverse Stock Split Effective Today JERSEY, Channel Islands, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that a reverse split of its ordinary shares, nil par value ("Ordinary Shares"), at a ratio of 1-for-40 became effective following close of trading on the Nasdaq Global Market today. The Company's Ordinary Shares will begin trading on a split-adjusted basis when the market opens on November 3, 2022 under the existing trading symbol, "QTNT." The reverse stock split i...

 PRESS RELEASE

Quotient Limited Announces Intent to Effect Reverse Stock Split

Quotient Limited Announces Intent to Effect Reverse Stock Split JERSEY, Channel Islands, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that it will effect a one-for-40 reverse stock split ("Reverse Stock Split") of its ordinary shares, nil par value ("Ordinary Shares") that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market ("Nasdaq"). The Company's Ordinary Shares are expected to begin trading on a split-adjusted basis when ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 17, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch